Michelle LaSpaluto
Director of Finance/CFO bei CHIMERIX, INC.
Vermögen: 117 659 $ am 31.03.2024
Profil
Michelle LaSpaluto is currently the Chief Financial Officer at Chimerix, Inc. since 2023.
Previously, she worked as the Senior Director-Accounting at AlphaVax, Inc. from 2000 to 2011.
Ms. LaSpaluto completed her undergraduate degree at Michigan State University and holds an MBA from East Carolina University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CHIMERIX, INC.
0,12% | 14.02.2024 | 110 999 ( 0,12% ) | 117 659 $ | 31.03.2024 |
Aktive Positionen von Michelle LaSpaluto
| Unternehmen | Position | Beginn |
|---|---|---|
| CHIMERIX, INC. | Director of Finance/CFO | 01.12.2023 |
Ehemalige bekannte Positionen von Michelle LaSpaluto
| Unternehmen | Position | Ende |
|---|---|---|
AlphaVax, Inc.
 AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Comptroller/Controller/Auditor | 01.06.2011 |
Ausbildung von Michelle LaSpaluto
| Michigan State University | Undergraduate Degree |
| East Carolina University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
